Early access to medicines scheme (EAMS) scientific opinion: venetoclax for the treatment of chronic lymphocytic leukaemia (CLL)

This publication was withdrawn on

Withdrawn as this product received a marketing authorisation from the European Commission.

EAMS scientific opinion given to venetoclax to treat a type of blood cancer in adults known as chronic lymphocytic leukaemia, including the public assessment report.